<DOC>
	<DOCNO>NCT02000427</DOCNO>
	<brief_summary>This study seek adult subject R/R Ph+ B-precursor ALL . This single-arm Simon II stage design , multicenter study consist screen period , induction treatment period ( 2 cycle blinatumomab ) , consolidation treatment period ( 3 additional cycle blinatumomab applicable subject ) , safety follow-up visit 30 day treatment . Following safety follow-up visit , subject follow response duration survival every 3 month 18 month death , whichever occur first .</brief_summary>
	<brief_title>Phase 2 Trial Blinatumomab Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Patients Ph+ Bprecursor ALL , follow : • Relapsed refractory least one second generation TKI ( dasatinib , nilotinib , bosutinib , ponatinib ) OR intolerant second generation TKI intolerant refractory imatinib mesylate Greater 5 % blast bone marrow Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Age ≥ 18 year age , time informed consent . Subject provide informed consent subject 's legally acceptable representative provide informed consent subject kind condition , opinion Investigator , may compromise ability subject give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Relapsed ; Refractory ; Philadelphia Positive ; B-precursor ; Acute Lymphoblastic Leukemia ; ALL ; Blinatumomab ; Leukemia ;</keyword>
</DOC>